Mizuho raised the firm’s price target on Charles River (CRL) to $200 from $174 and keeps a Neutral rating on the shares as part of its 2026 outlook for managed care and health facilities. The firm believes 2026 will be a “pivotal year” for managed care. The sector is at the end of a three-year negative underwriting cycle and margins should improve in commercial, Medicaid and Medicare over the next few years, the analyst tells investors in a research note. As a result, Mizuho is positive on managed care heading into 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River price target raised to $190 from $165 at JPMorgan
- BofA shakes up ratings in Biopharma Services with seven changes
- Charles River upgraded to Buy from Neutral at BofA
- Charles River price target raised to $215 from $210 at Barclays
- Early notable gainers among liquid option names on December 3rd
